Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.
Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, New York.
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1291-1295. doi: 10.1210/jc.2017-01939.
The nonthyroidal illness syndrome (NTIS) is a constellation of changes in circulating thyroid hormone levels that occur in euthyroid patients with acute or chronic systemic diseases. The changes that occur include a reduction in serum T3, an increase in serum rT3, and variable changes in circulating T4 levels. No consensus exists regarding therapeutic intervention for NTIS.
We briefly review the published literature on the physiological actions of T4 and of rT3-hormones that until recently have been seen to have little or no bioactivity-and analyze the apparent significance of changes in circulating T4 and T3 encountered in the setting of NTIS in patients with cancer. In the case of T4, these actions may be initiated at a cancer or endothelial cell plasma membrane receptor on integrin αvβ3 or at the cytoskeleton.
This review examines possible therapeutic intervention in NTIS in patients with cancer in terms of T4 reduction and T3 support. Evidence also exists that rT3 may support cancer.
Prospective study is proposed of pharmacological reduction of normal or elevated T4 in cancer-associated NTIS. We also support investigation of normally circulating levels of T3 in such patients.
非甲状腺疾病综合征(NTIS)是一种循环甲状腺激素水平变化的综合征,发生在患有急性或慢性全身疾病的甲状腺功能正常的患者中。发生的变化包括血清 T3 减少、血清 rT3 增加以及循环 T4 水平的变化。对于 NTIS 的治疗干预,目前尚无共识。
我们简要回顾了关于 T4 和 rT3 的已发表文献——这些激素直到最近才被认为具有很少或没有生物活性——并分析了在癌症患者 NTIS 背景下循环 T4 和 T3 变化的明显意义。就 T4 而言,这些作用可能在整合素 αvβ3 的癌细胞或内皮细胞膜受体或细胞骨架处开始。
本综述根据 T4 减少和 T3 支持检查了癌症患者 NTIS 中的可能治疗干预。也有证据表明 rT3 可能支持癌症。
拟对癌症相关 NTIS 中正常或升高的 T4 进行药理学降低进行前瞻性研究。我们还支持对此类患者正常循环 T3 水平的研究。